| [1] |
冯晓霞,黄小燕,陈钦. 特发性膜性肾病的临床及肾脏病理特点对疗效影响因素分析[J]. 中国中西医结合肾病杂志,2024,25(4):333-335.
|
| [2] |
中华中医药学会肾病分会,广东省中医药学会肾病专业委员会,杨丽虹,苏佩玲,等. 特发性膜性肾病中医临床实践指南(2021)[J]. 中国全科医学,2023,26(6):647-659.
|
| [3] |
LIANG J, HAO W, XIA F, et al. Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy[J]. Ren Fail, 2023, 45(1): 2212081. doi:10.1080/0886022x.2023.2212081
doi: 10.1080/0886022x.2023.2212081
|
| [4] |
王钢,沈兰. 特发性膜性肾病中医,中西医结合辨析经验[J].中国中西医结合肾病杂志, 2023, 24(1):1-5.
|
| [5] |
SUN W, ZHU C, LI Y, et al. B cell activation and autoantibody production in autoimmune diseases[J]. Best Pract Res Clin Rheumatol, 2024, 38(2): 101936. doi:10.1016/j.berh.2024.101936
doi: 10.1016/j.berh.2024.101936
|
| [6] |
姚重华,张娜,顾明珠,等. 沈氏清肾汤对阴虚内热型狼疮性肾炎患者尿蛋白及血清BAFF的影响[J]. 西部中医药,2022,35(12):129-132.
|
| [7] |
CHEUNG C K, ALEXANDER S, REICH H N,, et al. The pathogenesis of IgA nephropathy and implications for treatment[J]. Nat Rev Nephrol, 2025, 21(1): 9-23. doi:10.1038/s41581-024-00885-3
doi: 10.1038/s41581-024-00885-3
|
| [8] |
DONG Z, LIU Z, DAI H,et al. The potential role of regulatory B cells in idiopathic membranous nephropathy[J]. J Immunol Res, 2020, 2020(1): 7638365. doi:10.1155/2020/7638365
doi: 10.1155/2020/7638365
|
| [9] |
RAJAGOPAL V, LEKSA N, GORHAM R, et al. SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb[J]. Blood Adv, 2023, 7(16): 4258-4268. doi:10.1182/bloodadvances.2022009028
doi: 10.1182/bloodadvances.2022009028
|
| [10] |
谌璞.肾内科学[M]. 2版. 北京:人民卫生出版社,2015:39-54.
|
| [11] |
VERVOORT G, WILLEMS H L, WETZELS J F M. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: Validity of a new (MDRD) prediction equation[J]. Nephrol Dial Transplant, 2002,17(11): 1909-1913. doi:10.1093/ndt/17.11.1909
doi: 10.1093/ndt/17.11.1909
|
| [12] |
CATTRAN D C, FEEHALLY J, COOK H T, et al. Kidney Disease:Improving Global Outcomes (KDIGO)Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis[J]. Kidney Int Suppl,2012,2(1):139-274.
|
| [13] |
邱明珠,付晓宇,曾也婷,等. 特发性膜性肾病79例临床病理特征及预后分析[J]. 临床与实验病理学杂志,2021,37(11):1301-1307.
|
| [14] |
常美莹,潘知玉,赵明明,等. 特发性膜性肾病临床病理特点及纤维蛋白原的临床意义[J]. 暨南大学学报(自然科学与医学版),2023,44(2):179-185.
|
| [15] |
CHI M, MA K, WANG J, et al. The immunomodulatory effect of the gut microbiota in kidney disease[J]. J Immunol Res, 2021, 2021(1): 5516035. doi:10.1155/2021/5516035
doi: 10.1155/2021/5516035
|
| [16] |
谢海清,朱玲珍,覃嫏颖,等. 血清B细胞活化因子水平对狼疮肾炎患儿疾病活动度及预后的评估价值[J]. 标记免疫分析与临床,2020,27(9):1578-1582.
|
| [17] |
SCHUBART A, FLOHR S, JUNT T, et al. Low-molecular weight inhibitors of the alternative complement pathway[J]. Immunol Rev, 2023, 313(1): 339-357. doi:10.1111/imr.13143
doi: 10.1111/imr.13143
|
| [18] |
陈香慧,贾婷,杨莹,等. 尿蛋白/肌酐比与24-h尿蛋白定量在肾小球疾病尿蛋白水平测量中的一致性评价[J]. 首都医科大学学报, 2024, 45(5):831-837.
|
| [19] |
SO B Y F, YAP D Y H, CHAN T M. B Cells in Primary Membranous Nephropathy: Escape from Immune Tolerance and Implications for Patient Management[J]. Int J Mol Sci,2021,22(24):13560. doi:10.3390/ijms222413560
doi: 10.3390/ijms222413560
|
| [20] |
THURMAN J M. Complement and the Kidney: An Overview[J]. Adv Chronic Kidney Dis,2020,27(2):86-94. doi:10.1053/j.ackd.2019.10.003
doi: 10.1053/j.ackd.2019.10.003
|
| [21] |
史美萍,金钟大. 成人特发性膜性肾病临床病理特征及预后分析[J]. 临床肾脏病杂志,2024,24(7):543-549.
|
| [22] |
ONISZCZUK J, BELDI-FERCHIOU A, AUDUREAU E, et al. Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults[J]. Nephrol Dial Transplant,2021, 36(4): 609-617. doi:10.1093/ndt/gfaa279
doi: 10.1093/ndt/gfaa279
|
| [23] |
WEN L, LI Q, CHENG G, et al. Prognostic value of serum complement cleavage factor Bb in idiopathic membranous nephropathy and establishment of nomogram model[J]. Sci Rep, 2024, 14(1): 27266. doi:10.1038/s41598-024-78325-2
doi: 10.1038/s41598-024-78325-2
|
| [24] |
任海霞,刘菊红,李佳,等. 血清MBL、BAFF与磷脂酶A2受体相关特发性膜性肾病患者肾功能及疗效的关系[J]. 山东医药,2024,64(19):35-39.
|